HutchMed launches $602m secondary listing in Hong Kong

Jonathan Breen

June 18, 2021 08:15 am

Giupry, France, june 15th 2020 The test developed by the company NG Biotech allows, from a drop of blood, to identify in 15 minutes the specific antibodies produced by the organism during infection with the SARS-CoV-2 virus. It is the first ultra-rapid blood test manufactured and clinically validated in France. | Vincent Michel/Maxppp/PA Images

Biopharmaceutical company HutchMed (China) kicked off the roadshow for its HK$4.68bn ($602.7m) Hong Kong IPO on Friday, placing more than half of the shares in its third listing with cornerstone investors.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

Macquarie Group Deutsche Bank Credit Suisse Equity IPOs Health and Biotech China Merchants Securities Co Equity China Merchants Bank Co China International Capital Corp Jefferies LLC Hong Kong SAR Asia Greater China Northeast Asia Asia Pacific SRI Morgan Stanley Emerging Markets HSBC

JB

Jonathan Breen

Equities editor GlobalCapital Asia